Trial reportBMC anesthesiology2025
Comparison of hemodynamics and respiratory function between ciprofol-remifentanil and propofol-remifentanil in obese patients undergoing gastrointestinal endoscopic anesthesia: a randomized controlled trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo assess the safety of ciprofol for painless gastroenteroscopy in obese patients by comparing the effects of ciprofol-remifentanil and propofol-remifentanil on hemodynamic parameters, respiratory function, and other adverse reactions.
methodsA total of 70 obese patients who underwent painless gastrointestinal endoscopy at Longyan First Hospital of Fujian Medical University (Longyan, China) from September 2023 to February 2024 were enrolled. They were randomly assigned into the propofol group (Group A) and the ciprofol group (Group B) by a random number table. Group A received propofol combined with remifentanil anesthesia during the endoscopy, while Group B received ciprofol combined with remifentanil anesthesia. The systolic blood pressure, diastolic blood pressure, heart rate, and peripheral capillary oxygen saturation (SpO
resultsCompared with Group A, Group B exhibited significantly higher blood pressure levels at T1 and T2, as well as higher SpO₂ levels at T1, T2, and T3 (P < 0.05). The incidence of hypotension was lower in Group B (P < 0.05), and no significant differences were identified in arrhythmias, tachycardia, bradycardia, or the use of vasoactive drugs between the two groups. Group B also demonstrated a lower incidence of hypoxemia, reduced average severity, shorter duration, and a higher minimum SpO₂ level compared with Group A (P < 0.05). Additionally, Group B required fewer jaw thrust interventions (P < 0.05) and had a significantly lower incidence of injection pain (P < 0.05). No significant differences were found in the incidence of other adverse reactions between the two groups.
conclusionThe ciprofol-remifentanil combination used in painless gastroenteroscopy in obese patients resulted in more stable hemodynamics, significantly reduced respiratory depression, and less injection pain.
trial registrationThe trial was registered in the China Clinical Trials Registry (Registration No. ChiCTR2300075619, Date of registration: 11/09/2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.